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ABSTRACT  
Background: Bronchoalveolar mesenchymal stem cells (MSCs) play an important role in the 
maintenance of lung integrity. Therapeutic application of bone marrow-derived MSCs 
reduced chronic bronchial inflammation in idiopathic pulmonary fibrosis, and improved the 
ratio of survivors in sepsis with pneumonia. This study investigated the effect of MSCs from 
bronchoalveolar lavage fluid (BALF) of hypersensitivity pneumonitis (HP) on T-cell function 
under in vitro conditions.  
Methods: Bronchoalveolar MSCs were obtained via bronchoscopy with BAL from children 
with severe subacute HP. As control, BALF MSCs were assessed from children without any 
inflammatory lung disease. Isolated MSCs were characterized via immunophenotyping by 
flow cytometry and confocal laser scanning microscopy. HP-derived and healthy separated 
peripheral blood mononuclear cells (PBMCs) were stimulated by 5 µg/mL 
phytohemagglutinin in the presence of HP-derived or control MSCs in 5-day cultures. 
Proliferation and activation of T-cells were characterized by the mean fluorescence intensity 
(MFI) of 5,6-carboxyfluorescein-diacetat succinimidyl ester (CFSE) and CD25, CD69 as well 
as HLA-DR surface positivities, respectively. 
Results: HP-derived MSCs showed significantly lower level of CD73, CD90 and CD105 
expression compared to control MSCs in both flow cytometric and confocal microscopic 
experiments. MSCs from HP did not reduce T-cell proliferation based on CFSE MFI values, 
while the level of CD25 expression on both control and HP-derived CD4+ and CD8+ T-cells 
was significantly reduced by normal MSCs, while HP-derived MSCs did not have any 
significant effect. The level of other activation markers was not markedly modulated by 
MSCs. 
Conclusions: BALF MSCs from HP are unable to downregulate the proliferation and 
activation of T-cells that may support the development of recurrent intrapulmonary 
inflammation in HP. 
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Introduction 
Mesenchymal stem cells (MSCs) are multipotent progenitor cells that were originally 
identified in the bone marrow (BM) (1), and since then these cells have been detected and 
isolated from many tissues including the lungs (2). Lung residual MSCs are present at the 
bronchoalveolar duct junctions and in the alveolar walls (3), and can be cultured from 
bronchoalveolar lavage fluid (BALF) samples (4). Isolated MSCs can be easily identified by 
flow cytometry via their positivity for CD105, CD73, and CD90 as well as the absence of 
CD45 and CD34 expression (5). These cells inhibit inflammation, contribute to epithelial 
tissue repair, and maintain tissue integrity in severe conditions such as sepsis (6). Normal 
MSCs possess immunomodulatory properties including the suppression of T- and B-cell 
proliferation, alteration of dendritic cell function, and modulation of natural killer cells and 
macrophages (7). For instance, in a murine asthma model, BM-derived MSCs markedly 
suppressed chronic bronchial inflammatory processes (8). Hence, according to the current 
understanding MSCs hold great promise for the treatment of severe inflammatory disorders 
(9). On the contrary, abnormal MSCs from BM of hematological disorders showed decreased 
CD90 positivity with a loss of immunosuppressive activity versus healthy counterparts (10).  
Hypersensitivity pneumonitis (HP) is a spectrum of relatively rare diffuse, 
inflammatory, immune-mediated interstitial lung disease (ILD). In children, it is usually 
caused by the repetitive inhalation of two major environmental agents: bird (feather) allergens 
and antigens consisting of fungal spores (11). Analysis of cellular content in BALF improves 
the diagnostic accuracy in these diseases by revealing the predominately high percentage of 
CD8+ T-lymphocytes, the alteration in CD4/CD8 ratio with increased levels of 
immunoglobulins and albumin in BALF (11). The exacerbated immune response to HP-
causing antigens is a pivotal event in the pathomechanism of HP modulated by 
CD4+/CD25+/FoxP3+ regulatory T cells (Treg) without a substantial activity to suppress 
lymphocyte proliferation. Consequently, the fraction of CD4+/CD25+ T-cells in the whole 
CD4+ population in BALF was highly elevated in active HP subjects, and the maturation of 
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dendritic cells caused pro-inflammatory mediator production (e.g. IL-17 and tumor necrosis 
factor-α) that also inhibited Treg cell function (12). Beside these facts, further investigations 
are required to elucidate the role of other impaired immunological events (e.g. defective 
bronchoalveolar MSCs) in HP. 
The objective of the present study was to reveal whether BALF MSCs obtained from 
children with severe subacute HP had any immunomodulatory effect in comparison to normal 
MSCs from control patients. 
 
Methods 
Patients and BALF samples 
The National Ethics Committee, Medical Research Council, Budapest, Hungary approved the 
trial (number: 7270-1-2012/EKU) in accordance with the Declaration of Helsinki. Written 
informed consent was obtained from the parent or legal guardian of each child before any 
investigation. Three children (2 females, 1 male, aged 6-10 years) with subacute clinical 
forms of HP were recruited into this study, who had specific serum antibodies to feather or 
moulds, and ground glass and linear opacities were observed on HRCT. Bronchoscopy and 
BAL were performed as described previously (13). The cellular analysis was performed 
immediately after the BAL procedure. As control, three children (2 females, 1 male, aged 3-
16 years) were involved with suspicious foreign body aspiration or psychogenic cough. 
Bronchoscopy and BAL excluded any chronic immune-mediated disorders or diffuse 
parenchymal lung diseases without signs of any type of inflammation. 
 
Isolation and culturing of lung-derived MSCs  
Recovered BALF samples were first filtered through a sterile strainer to remove non-cellular 
particulate materials, and the cell pellet was recovered by centrifugation at 800 g for 10 
minutes. 6 x 105 cells in BALF samples were seeded in a T-25 tissue culture flask (Biotech-
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Hungary, Budapest, Hungary), and incubated in RPMI-1640 medium (Sigma-Aldrich Co. 
Ltd., Dorset, England) supplemented with 1.0% fetal bovine serum (Sigma-Aldrich), sodium-
pyruvate (Sigma-Aldrich), and penicillin-streptomycin-amphotericin (Sigma-Aldrich) at 37°C 
in 5% CO2 / 95% air atmosphere. Medium was changed every 3 days, and after 2-3 weeks of 
incubation, BALF cells gave rise to a confluent cell layer. By consecutive passages most non-
adherent contaminating cells, i.e. macrophages were effectively removed and the adherent 
fibroblastoid colonies were expanded by weeks 3-4.  
 
Identification of bronchoalveolar MSCs by flow cytometry and CLSM  
MSC colonies were harvested by treatment with trypsin (Gibco, Life Technologies, Vienna, 
Austria) at day 6 to 10 from the initiation of culturing (passage 2-3) and were aliquotted at the 
concentration of 0.5 x 105/mL. Cells were labeled with fluorochrome conjugated anti-human 
CD105-APC, CD73-PE, CD90-PerCP-Cy5.5 and CD34-FITC monoclonal antibodies or 
isotype-matched control mouse IgG (BD, San Jose, CA) at the recommended concentration 
(5), then washed in PBS and fixed in 1% PFA, and surface positivities were evaluated using a 
flow cytometer (FACSCalibur; BD) (Figure 1A). Before flow cytometric analysis, Calibrite 
beads (BD) (a three-color kit supplemented with APC- and PerCP-Cy5.5-labeled beads) were 
used monthly to adjust instrument settings, to set fluorescence compensation and to check 
instrument sensitivity. Cells were considered to be positive for a given antigen if their 
fluorescence intensity was higher than the 95th percentile of cells stained with an isotype 
control antibody. The mean fluorescence intensity (MFI) of positive cells was determined by 
subtracting the MFI of the control sample from the MFI of cells stained with the appropriate 
antibody. MSCs were also investigated by confocal laser scanning microscopy (CLSM; 
FluoView FV1000, Olympus, Tokyo, Japan) to study the level of coexpression of their 
receptor profile using the same set of antibodies. CD105-APC was excited at 633 nm and its 
fluorescence was detected in the spectral range between 650-750 nm. CD73-PE and CD90-
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PerCP-Cy5.5 were excited at 488 nm and their emission was measured between 500-600 nm 
and 650-750 nm, respectively. Due to the absorption of Cy5.5 in the tandem dye PerCP-Cy5.5 
at 633 nm, the overspill of PerCP-Cy5.5 intensity to the APC channel was strong. Therefore, 
the overspill compensation factor was determined using cells labeled with CD90-PerCP-
Cy5.5 only and pixel-by-pixel correction was performed for samples labeled with both CD90-
PerCP-Cy5.5 and CD105-APC using DipImage (University of Technology, Delft, The 
Netherlands) in Matlab (Mathworks, Inc., Natick, MA). Ten visual fields were observed at 
random in each cell culture (Figures 1B and C). 
 
Coculture of PHA-stimulated PBMCs and MSCs 
PBMCs were separated from the buffy-coat of healthy volunteers using Ficoll-Histopaque-
1077 density gradient (Sigma-Aldrich). HP-derived or control MSCs (2 x 104 cells/well) were 
adhered on a 96-well plate (Sigma-Aldrich) for 4 hours, and treated with mitomycin C (10 
µg/mL) for 2 hours. These cells were washed three times in PBS. Normal and HP-derived 
isolated PBMCs (2 x 105 cells/well) were resuspended in 400 µL DMEM (Gibco, Life 
Technologies) with 10% autologous serum and then stimulated by phytohemagglutinin (PHA, 
Sigma-Aldrich) at the final concentration of 5 µg/mL. HP and control MSCs were separately 
cultured with either normal or HP-derived PBMCs in RPMI-1640 medium at 37°C, 5% CO2 
for 5 days. As control samples, untreated and PHA-stimulated PBMCs were plated into the 
wells in the absence of MSCs.  
 
Analysis of T-cell activation 
After culturing for 5 days both types of PBMCs were simultaneously harvested, washed twice 
in PBS, and stained by anti-CD4-FITC and anti-CD8-PE antibodies along with anti-CD25-
APC, anti-CD69-PerCP-Cy5.5, and anti-HLA-DR-PerCP antibodies (BD) followed by flow 
cytometry to analyze T-cell activation in both subgroups. 
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T-cell proliferation assay 
To monitor lymphocyte division, both HP and control PBMCs were stimulated with 5 µg/mL 
PHA in the presence or absence of either abnormal or healthy MSCs for 5 days and were 
stained with 1.7 µM 5,6-carboxyfluorescein N-succinimidyl ester (CFSE) (Sigma-Aldrich) 
according to the manufacturer’s instructions. PBMCs were then harvested, washed in fresh 
culture media, and after using anti-CD4-APC and anti-CD8-PE antibodies (BD) for 15 
minutes, the alteration of mean fluorescence intensity (MFI) of CFSE in CD4+ and CD8+ T-
cells was measured in the FL1 channel with a 530/30 filter. 
 
Statistical analysis 
Results were expressed as mean±standard deviation (SD). Normally distributed variables 
were analyzed by using two-tailed Student’s independent samples t test. Differences in 
various activation markers among samples at different time points were tested by analysis of 
variance (ANOVA) followed by Tukey’s HSD test. P values <0.05 were considered 
statistically significant. All analyses were performed using the SPSS Statistics software, 
version 19.0 (IBM Corp., Armonk, NY, USA).  
 
 
Results 
Characteristics of BALF samples 
Total cell count in HP BALF samples was 9.5-13.0 x 105/mL (normal value: 1.0-1.5 x 
105/mL) with elevated number of lymphocytes (3.6-8.3 x 105/mL) and macrophages (2.7-7.5 
x 105/mL) and moderately altered neutrophil count (0.1-1.3 x 105/mL). According to flow 
cytometry, 61±11%, 38±24% and 23±12% of the lymphocytes were positive for CD3, CD4 
and CD8, respectively. Control patients had normal BALF cytology (1.0 x 105/mL 
Page 7 of 33
John Wiley and Sons, Inc.
Cytometry: Part B - Clinical Cytometry
This article is protected by copyright. All rights reserved.
  8 
macrophages, 0.1 x 105/mL lymphocytes, 0.01 x 105/mL neutrophils) at mean total cell count 
of 1.15 x 105/mL.  
 
Identification and characterization of MSCs from HP and normal BALF 
Both in control subjects and HP patients, MSCs showed positivity for CD73 (93.2±2.1% vs. 
97.3±3.7%), CD90 (90.6±1.3% vs. 99.2±0.4%) and CD105 (89.5±5.7% vs. 99.4±0.2%), and 
were negative for CD34 (data not shown). However, the MFI values in the positive cells were 
significantly (P<0.05) lower in the HP samples, compared to the controls, for CD73 
(132.7±11.3 vs. 290.7±15.6), CD90 (72.4±8.9 vs. 217.1±16.3) and CD105 (36.5±5.2 vs. 
60.7±3.8) (n=4-6) (Figure 1A). Furthermore, the expression pattern of the three MSC-specific 
antigens appeared to show substantially less overlap in HP (Figure 1C) vs. control MSCs 
(Figure 1B) when visualized by confocal microscopy (14) after staining any pairwise 
combination of CD73, CD90 and CD105. Assuming that the expression of these antigens is 
required for the development of the MSC phenotype, the decreased coexpression of the three 
antigens may lead to impaired MSC functions, which may even be associated with the 
impaired immunosuppressive effect of HP MSCs as suggested by Campioni et al. (10).  
 
HP-derived MSCs failed to inhibit T-lymphocyte proliferation  
The ratio of proliferating PBMCs in HP and control samples was determined based on the 
CFSE MFI values with the positive control sample (PBMCs with PHA) considered as 100%. 
Compared to the unstimulated PBMC-sample, 5 µg/mL PHA stimulation induced maximal 
proliferation of PBMCs in the absence of MSCs. The proliferation of normal and HP-derived 
T-cells was downregulated in the entire (CD3+) population in the presence of healthy MSCs 
to 33% and 45%, respectively, of the positive control sample (Figure 2A). Although this 
effect was statistically significant (p<0.01), this type of MSCs did not completely prevent 
proliferation since the CFSE MFI values of untreated negative control samples of normal and 
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HP-derived T-cells were 7-8% of the positive control. In contrast, MSCs from HP could not 
suppress T-lymphocyte proliferation induced by this mitogenic agonist since the CFSE MFI 
values were 89% and 86% of the positive control sample for normal and HP-derived T-cells, 
respectively. Statistical analysis revealed a significantly higher fraction of proliferating 
lymphocytes in the presence of HP-derived MSCs compared to control MSCs (P<0.05) 
(Figure 2A). Selective evaluation of the proliferation of CD4+ and CD8+ T-cells revealed that 
control MSCs could also inhibit the proliferation of T-lymphocytes, while HP-derived MSCs 
were without effect (data not shown). 
 
T-cell activation was not suppressed by MSCs from HP in contrast to normal MSCs  
We intended to analyze whether MSCs in HP were unable to modulate the activation of either 
normal or HP-derived CD4+ and CD8+ T-cells. First, PHA stimulation caused a significant 
elevation in the fraction of CD25+ cells among CD4+ T-cells from healthy donors 
(17.2±2.5% after PHA stimulation vs. 1.9±0.9% in unstimulated cells) and children suffering 
from HP (19.8±3.4% after PHA stimulation vs. 2.5±0.8% in unstimulated cells; Figures 2B 
and C). While normal MSCs significantly lowered the CD25 positivity on CD4+ T-
lymphocytes from both healthy donors (5.7±1.2%) and HP patients (9.5±0.8%), the impact of 
MSCs from HP was not statistically significant (Figure 2B). Simultaneously, CD8+ T-cells 
were also analyzed, and in the same fashion, healthy MSCs depressed CD8+ T-cell activation 
shown by the reduced fraction of CD25+ cells in samples from healthy donors (8.2±1.8% and 
4.1±0.6% in the absence and presence of normal MSCs, respectively; P<0.05) and in samples 
from HP patients (7.9±1.9% and 4.6±1.2% in the absence and presence of normal MSCs, 
respectively; P<0.05). At the same time, abnormal HP-derived MSCs were unable to modify 
the activation of T-cells demonstrated by the fact that the CD25+ positivities in the absence of 
MSCs were similar to those measured in the presence of HP-derived MSCs cocultured with 
CD8+ T cells from healthy donors (7.8±1.6%) and HP patients (9.1±1.7%). Hence, there was 
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a significant difference between the effect of control and HP MSCs in this regard as well 
(P<0.05). In parallel, there was a similar but only minor change in CD69 and HLA-DR 
expression on both types of T-lymphocytes from normal and HP samples (data not shown).  
 
Discussion 
MSCs are in the focus of interest due to their regulatory role in immune responses (6-9). Most 
data are available from animal models using human BM-derived MSCs in asthma (8), in acute 
lung injury (15), in pulmonary fibrosis (16) and in acute respiratory distress syndrome with 
sepsis (6). However, there is no data about the immunoregulatory activity of BALF MSCs in 
HP. 
Due to the impaired lymphosuppressive function of Treg cells showing decreased FoxP3 
expression lymphocytes are free to proliferate and accumulate in the lung (12). We believed 
that nonfunctional lung resident MSCs might be also involved in the impaired immune 
tolerance. First, we characterized BALF MSCs via immunophenotyping and decreased level 
of CD105, CD73, and CD90 was observed in HP MSCs by flow cytometry and CLSM 
similarly to MSCs from BM of hematological diseases showing a loss of immunosuppressive 
activity (10). Then we investigated the immunoregulatory effect of MSCs obtained from 
BALF samples from patients with subacute HP in comparison to that of normal cells. T-cells 
upregulate surface activation markers CD25, CD69 and HLA-DR induced by PHA (17), thus 
we studied these markers of T-lymphocytes cocultured with MSCs. Isolated MSCs from HP 
had a significantly lower effect on T-cell function than normal MSCs, which substantially 
reduced CD4+ and CD8+ T-cell proliferation and activation with decreased CD25 positivity. 
However, the level of other activation markers was not markedly affected. Furthermore, 
healthy BM-derived MSCs (18) and normal BALF MSCs (19) induced a similar degree of 
division arrest anergy in both subtypes of T-cells. In contrast to our data, Glennie et al. did 
not observe an alteration in CD25 positivity by healthy BM-derived MSCs (18). In BALF 
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samples from active HP patients, the level of CD4+/CD25+ T-cells was much higher 
supporting the significance of these lymphocytes in this ILD (12). Since we found a 
significant difference in the ratio of reactive CD25+ T-cells in the presence and absence of 
functional BALF MSCs in cell cultures, we presume that nonfunctional MSCs in HP may 
highly participate in processes leading to the raised level of disease-associated reactive T-cells 
in the lung.  
The rarity of HP in childhood prevented us from recruiting more patients into this study, 
which limits statistical robustness of the conclusions. However, we had striking differences 
between the control and HP-derived MSCs on T-cell function in vitro. These preliminary data 
also demonstrate that healthy MSCs can even influence HP-derived activated T-lymphocytes 
suggesting a potential therapeutic approach for HP by administrating isolated normal MSCs to 
these patients (20). However, further studies are required to confirm these alterations and to 
analyze the precise mechanism of abrogated lymphomodulatory effect of BALF MSCs in HP, 
e.g. in connection with their altered level of surface antigens (10). 
In conclusion, to the best of our knowledge, this is the first report to demonstrate the 
abnormal inhibitory capacity of bronchoalveolar MSCs on T-cell responses in this type of 
ILDs. These results suggest an additional cellular mechanism that allows a pro-inflammatory 
environment in HP. 
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Legend for Figures 
 
Figure 1. Flow cytometry (A) and CLSM (B, C) analysis of a population of BALF MSCs 
obtained from control (B) and HP (C) patients. Typical surface expression of CD73, CD90 
and CD105 were detectable by both techniques. Histograms of fluorescence intensity values 
of each parameter depicted that HP-derived MSCs showed a significantly lower level of these 
markers compared to control MSCs (A). Double staining of HP MSCs (C) and control cells 
(B) against the aforementioned antigens confirmed the flow cytometric results regarding 
lower expression in HP-derived MSCs. 
 
Figure 2. Analysis of the proliferation (A) and activation of PHA-stimulated CD4+ (B) and 
CD8+ (C) lymphocytes in the presence of normal and HP-derived MSCs. Via measuring 
CFSE positivity by flow cytometry, the proliferation of PBMCs stimulated by PHA was 
analyzed with HP-derived or normal bronchoalveolar MSCs (A). While normal MSCs were 
able to reduce proliferation of T-cells, HP-derived MSCs did not show a marked 
immunosuppressive effect on either normal or HP T-lymphocytes. Results were expressed as 
the ratio of proliferating PBMCs based on CFSE MFI values calculated from the positive 
control with 100% (mean±SD, n=3/experiment). T-cell activation was studied by flow 
cytometric detection of CD25 expression on CD4+ and CD8+ cells (B, C). When T-cells were 
cocultured with normal or HP MSCs, we found that normal MSCs significantly reduced the 
fraction of CD25+, activated T-cells, while HP-derived MSCs did not have such an effect 
under the same experimental conditions. Results are expressed in percent positivity 
(mean±SD, n=3/experiment). 
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